Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | FASN | P49327 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571943 | 1.00 | CYP2C9 (0.64) | CYP2C9MAPTSMN1; SMN2PTPN5KMT2A | |
| SCHEMBL7990521 | 1.00 | CYP2C9 (0.64) | CYP2C9MAPTSMN1; SMN2PTPN5KMT2A | |
| SCHEMBL197251 | 0.87 | MAPT (0.52) | CYP2C9MAPTKMT2ACYP1A2CYP2D6 | |
| SCHEMBL153694 | 0.87 | MAPT (0.52) | CYP2C9MAPTKMT2ACYP1A2CYP2D6 | |
| SCHEMBL4326795 | 0.87 | MAPT (0.52) | CYP2C9MAPTKMT2ACYP1A2CYP2D6 | |
| SCHEMBL198241 | 0.87 | MAPT (0.52) | CYP2C9MAPTKMT2ACYP1A2CYP2D6 | |
| SCHEMBL21557850 | 0.87 | MAPT (0.52) | CYP2C9MAPTKMT2ACYP1A2CYP2D6 | |
| SCHEMBL21229770 | 0.86 | CYP2C9 (0.57) | CYP2C9MAPTSMN1; SMN2PTPN5KMT2A | |
| SCHEMBL11846636 | 0.86 | CYP2C9 (0.47) | CYP2C9MAPTSMN1; SMN2KIF11NPC1 | |
| Water SCHEMBL6414988 | 0.85 | CYP1A2 (0.50) | CYP2C9MAPTKMT2ACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108901-A | Synthetic method of alpha-hydroxycarboxylic acid compound | 四川大学 | 2022-09-27 | — | — | CN | disclosed |
| CN-109689667-B | Porous chiral material and use thereof | 南开大学 | 2022-07-12 | — | — | CN | disclosed |
| US-10857517-B2 | Porous chiral materials and uses thereof | NANKAI UNIVERSITY (CN) | 2020-12-08 | — | — | US | disclosed |
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| US-6262073-B1 | INHIBITING THE ACTION OF A PRO-INFLAMMATORY CYTOKINE | OXIS INTERNATIONAL INC. | 2001-07-17 | — | — | US | disclosed |
| US-6136832-A | RACEMIC MIXTURES AND ENANTIOMORPHS | OXIS INTERNATIONAL INC. (US) | 2000-10-24 | — | — | US | disclosed |
| US-6005000-A | 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor | OXIS INTERNATIONAL, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0938482-A1 | 5-SUBSTITUTED AND 5,5-DISUBSTITUTED-3,4-DIHYDROXY-2(5H)-FURANONES AND METHODS OF USE THEREFOR | Oxis International, Inc. (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1998007714-A1 | 5-SUBSTITUTED AND 5,5-DISUBSTITUTED-3,4-DIHYDROXY-2(5H)-FURANONES AND METHODS OF USE THEREFOR | OXIS INTERNATIONAL, INC. (US) | 1998-02-26 | — | — | WO | disclosed |
| WO-1995023139-A1 | OPTICALLY PURE 4-ARYL-2-HYDROXYTETRONIC ACIDS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-08-31 | — | — | WO | disclosed |
| US-4386080-A | 3,4-DISUBSTITUTED-N-ACYLANILINES | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1983-05-31 | — | — | US | disclosed |
| EP-0040932-A1 | Amide derivatives, process for their manufacture and pharmaceutical or veterinary compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-12-02 | — | — | EP | disclosed |
| US-3941821-A | ANTIINFLAMMATORY, ANALGESICS, ANTIPYRETICS | WILLIAM H. RORER, INC. (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | CYP2C9 325/4885MAPT 4423/4885SMN1; SMN2 3242/4885 |
| US-10857517-B2 | Porous chiral materials and uses thereof | ANXA7, XDH, OPRM1 | CYP2C9 1318/4885MAPT 3329/4885SMN1; SMN2 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.